Quantcast

Latest Hepatocellular carcinoma Stories

2014-09-09 08:31:59

SAN ANTONIO, Sept. 9, 2014 /PRNewswire/ -- GenSpera, Inc. (OTCBB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, today announced that the United States Patent and Trademark Office (USPTO) issued patent 8,822,406 "Tumor Activated Prodrugs." The patent covers the composition of a specific prodrug activated by Prostate Specific Antigen (PSA) that is designed to deliver a thapsigargin derivative selectively to prostate cancers. PSA is an enzyme...

2014-09-08 12:28:40

- In vivo data support potential clinical benefit of first therapeutic to target a defined subset of liver cancer patients based on genetic profile - CAMBRIDGE, Mass., Sept. 8, 2014 /PRNewswire/ -- Blueprint Medicines today announced the presentation of preclinical data investigating BLU-554, a first-in-class selective fibroblast growth factor receptor 4 (FGFR4) inhibitor, for the treatment of patients with hepatocellular carcinoma (HCC). Results demonstrate in vivo efficacy,...

2014-09-08 08:30:50

Highly Attended Celsion-Sponsored Symposium on Current Concepts for Treating Intermediate HCC included: New Paradigm in Staging HCC Patients; Phase III Studies in HCC; and Advances in Image Guided Radiofrequency Ablation LAWRENCEVILLE, N.J., Sept. 8, 2014 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced highlights from three presentations by three of the world's leading liver cancer experts and principal investigators for the Company's...

2014-09-08 08:30:26

50% of Patients Treated with Mipsagargin had No Tumor Growth at Four Months SAN ANTONIO, Sept. 8, 2014 /PRNewswire/ -- GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, presented the hepatocellular carcinoma (HCC), or liver cancer, Phase II clinical trial update for mipsagargin (G-202) at the 8(th) International Liver Cancer Association (ILCA) Conference on Saturday, September 6, 2014, in Kyoto, Japan. CEO, Craig Dionne, PhD,...

2014-09-05 23:00:54

Eleven-month Increase in Median OS Reported with VT-122 plus Sorafenib, Compared to Sorafenib Alone. Data Presented at International Liver Cancer Association Conference. MORRISTOWN, N.J (PRWEB) September 05, 2014 Vicus Therapeutics, an immuno-oncology company focused on bringing breakthrough immunotherapies to patients with solid-tumor cancers, announced positive results from a Phase II randomized, open-label, controlled clinical trial of its lead compound, VT-122, in combination with...

2014-09-05 08:23:08

In preclinical studies, CF102 induces hepatocyte proliferation resulting in improved liver status PETACH TIKVA, Israel, Sept. 5, 2014 /PRNewswire/ -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer and inflammatory diseases, today announced the issuance of Patent No. 2010-529501, titled, "Method for inducing hepatocyte proliferation and uses thereof," by the Japanese Patent...

2014-09-04 08:31:36

ThermoDox® Combined with Mild Local Hyperthermia is Safe and Produces Compelling Objective Local Responses in RCW Breast Cancer Patients LAWRENCEVILLE, N.J., Sept. 4, 2014 /PRNewswire/ -- September 4, 2014 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN) today announced that data from two Phase I studies on ThermoDox® in recurrent chest wall breast cancer were published in the International Journal of Hyperthermia. The article, titled "Two phase 1...

2014-09-04 08:29:50

Pharmacokinetics, Safety and Tolerability of NVR-1221 Support Advancement to Phase 1b Clinical Studies in Patients with Chronic HBV Infection DOYLESTOWN, Pa., Sept. 4, 2014 /PRNewswire/ -- Novira Therapeutics, Inc., a privately held biopharmaceutical company developing novel therapies for curative treatment of chronic hepatitis B virus (HBV) infection, today announced successful completion of a Phase 1a clinical study of NVR-1221. The results for the Phase 1a clinical study...

2014-09-03 08:33:52

Mipsagargin Contains New Pre-Stem "Gargin," Defining a Unique Pharmacologic Group Unlike Any Drug Currently or Previously on the Market SAN ANTONIO, Sept. 3, 2014 /PRNewswire/ -- GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, today announced that the World Health Organization's (WHO) International Nonproprietary Name (INN) group has recommended the generic name "mipsagargin" (mip sa gar' jin) for its lead drug candidate, also...

2014-09-02 08:30:12

Kyungpook National University Hospital in South Korea Treats the First Patient in the 14 Country, 100 Site Global Study LAWRENCEVILLE, N.J., Sept. 2, 2014 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that the first patient has been enrolled in its pivotal Phase III OPTIMA Study of ThermoDox® in combination with optimized radiofrequency ablation (RFA) in patients with primary liver cancer, also known as hepatocellular...


Latest Hepatocellular carcinoma Reference Libraries

Hepatitis B
2013-02-25 09:11:23

Image Caption: This electron micrograph reveals the presence of hepatitis-B virus HBV "Dane particles", or virions. Credit: CDC/Wikipedia Hepatitis B: What Is It? Hepatitis simply means a swelling or inflammation of the liver. The type hepatitis that a person contracts (there are 5 common forms) affects their long-term prognosis. The most common and most severe of these different types of liver infection is Hepatitis B, which is caused by the hepatitis B virus (HBV). It is typically...

45_36624a455e3cd9a4152b7670308f0ffa
2011-01-20 19:14:56

Hepatitis B virus, HBV, is a part of the Hepadnaviridae family of viruses. HBV can lead to cirrhosis and hepatocellular carcinoma and has been linked to pancreatic cancer. It is classified as a species of the Orthohepadnavirus. Similar viruses have been found worldwide in great apes and monkeys. There a few different genotypes and they all differ by at least 8% of the sequence and have distinct geographical distributions and this has been associated with anthropological history. Type A is...

0_9255b919f71eff1fd4202c1dbb1795d2
2011-01-12 15:49:29

Hepadnaviruses can cause liver infections in humans and animals. The two recognized genera are Genus Orthohepadnavirus and Genus Avihepadnavirus. It has a small genome of partially double-stranded, partially single stranded circular DNA. It is a group 7 virus that uses an RNA intermediate during replication. Most people who come into contact with the virus are able to clear the infection alone although some cannot and usually progress to fulminant hepatitis. It can cause sever liver...

More Articles (3 articles) »
Word of the Day
conjunto
  • A style of popular dance music originating along the border between Texas and Mexico, characterized by the use of accordion, drums, and 12-string bass guitar and traditionally based on polka, waltz, and bolero rhythms.
The word 'conjunto' comes through Spanish, from Latin coniūnctus, past participle of coniungere, to join together; see conjoin